Accessibility Menu
Cue Biopharma logo

Cue Biopharma(NASDAQ) CUE

Current Price$34.28
Market Cap$140.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-90%
5 Year-89%
1 Year+26%
1 Month+18%
Cue Biopharma last closing stock price
MetricPriceDate
Last closeUSD 33.462026-07-21
Cue Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.97%USD 31.282026-07-14
1 month+17.57%USD 28.462026-06-18
3 month+92.27%USD 17.402026-04-22
Year to date+265.2%USD 9.162025-12-31
1 year+26.31%USD 26.492025-07-21
3 year-73.44%USD 126.002023-07-21
5 year-89.35%USD 314.102021-07-22
Since inception-90.41%USD 348.902018-01-02

Cue Biopharma Financials at a Glance

Market Cap

$140.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$32.73M

Net Income (TTM)

-$19.52M

EPS (TTM)

-$5.53

P/E Ratio

-6.05

Dividend

$0.00

Beta (Volatility)

1.49 (Average)

Price

$34.28

Volume

120,517.131

Open

$33.46

Previous Close

$34.20

Daily Range

$32.86 - $35.57

52-Week Range

$4.97 - $45.50

Estimated Earnings Date

Aug 18, 2026

CUE News

money-in-a-beaker-getty

3 Biotech Start-Ups That Could Soar in 2020

Cory RenauerJan 27, 2020
Pipette and test tube

3 Growth Stocks That Could Put Netflix's Returns to Shame

Anders BylundApr 20, 2018

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cue Biopharma

Cue Biopharma develops drugs that help the immune system fight cancer and other diseases. Its main products aim to activate specific immune cells for targeted treatment. These therapies are designed for patients with cancer, chronic infections, or autoimmune conditions.

Lab Bench to Bedside: Cue’s Main Offerings

  • Immuno-STAT Platform: Engineered proteins that direct immune cells to attack disease, used in all product candidates.
  • CUE-101: Drug in early clinical trials for cancers caused by human papillomavirus (HPV), targeting specific immune cells.
  • CUE-102: Drug candidate for cancers expressing a protein called WT1, aiming to boost immune response.
  • CUE-103: Targets cancers with a specific genetic mutation (KRAS G12V), including colon, lung, and pancreatic cancers.
  • CUE-200/300/400 Series: Early-stage programs for chronic infections and autoimmune diseases, not yet in clinical trials.

Growth Spurts and Strategic Moves

  • 2025: Signed collaboration with Boehringer Ingelheim for CUE-501, with upfront and milestone payments.
  • 2025: Regained Asian rights to CUE-101 from LG Chem Life Sciences; LG Chem keeps CUE-102 rights.
  • 2025: Raised $18 million in public offering; $10.8 million raised in 2024.
  • Ongoing partnership with Albert Einstein College of Medicine for research and technology development.

Why Cue Stands Out in the Crowd

Cue’s technology targets only disease-related immune cells, aiming to reduce side effects. Its modular drug platform allows quick adaptation for different diseases. The company relies on partnerships to share development risks and expand its reach.

Five Things You Need to Know

  • Collaboration revenue was $2.95 million in Q2 2025, up 11.1% year-on-year.
  • Operating loss improved to $8.6 million in Q2 2025, down from $10.4 million in 2024.
  • Cash and equivalents were $27.5 million as of June 30, 2025.
  • All revenue comes from research partnerships, not product sales.
  • Company faces ongoing losses and needs more funding by Q2 2026.

Bottom Line

Cue Biopharma is evolving through partnerships and a flexible drug platform. Its future depends on clinical progress and continued access to funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29

CEO

Usman Azam, MD

Website

www.cuebiopharma.com

Headquarters

Boston, MA 02139, US

CUE Financials

Key Financial Metrics (TTM)

Gross Margin

99.76%

Operating Margin

-59.83%

Net Income Margin

-59.65%

Return on Equity

-98.30%

Return on Capital

-86.59%

Return on Assets

-63.23%

Earnings Yield

-16.53%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$140.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.20M

Volume

120.52K

Avg. Volume

528.52K

Financials (TTM)

Gross Profit

$32.65M

Operating Income

-$19.58M

EBITDA

-$15.84M

Operating Cash Flow

-$24.46M

Capital Expenditure

-$148.00K

Free Cash Flow

-$24.61M

Cash & ST Invst.

$16.38M

Total Debt

$3.44M

Cue Biopharma Performance Analysis

Cue Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,245,227-91.7%
20232023-12-31USD 5,490,000340.9%
20242024-12-31USD 9,287,00069.2%
20252025-12-31USD 27,466,000195.7%
Cue Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30601.7%
Q32025-09-30-27.3%
Q42025-12-31921.0%
Q12026-03-31-74.1%
Cue Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -44.615.3%
20232023-12-31USD -33.26-25.4%
20242024-12-31USD -21.66-34.9%
20252025-12-31USD -8.42-61.1%
Cue Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3047.8%
Q32025-09-3016.9%
Q42025-12-31119.4%
Q12026-03-31-351.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$5.69M

+1250.6%

Gross Profit

$5.69M

+1250.6%

Gross Margin

100.00%

N/A

Market Cap

$140.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.85M

N/A

Employees

29

N/A

Net Income

-$5.18M

+57.8%

EBITDA

-$4.25M

+62.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$16.38M

+24.7%

Total Debt

$3.44M

-51.7%

Accounts Receivable

$7.25M

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.88M

+967.0%

Short Term Debt

$1.56M

-77.5%

Return on Assets

-63.23%

N/A

Return on Invested Capital

-83.39%

N/A

Free Cash Flow

-$11.06M

-32.9%

Operating Cash Flow

-$10.94M

-33.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EQEquillium, Inc.
$2.76+4.94%
IPSCCentury Therapeutics, Inc.
$2.15-4.02%
NRXPNRx Pharmaceuticals, Inc.
$4.48+0.45%
SPRBSpruce Biosciences, Inc.
$44.60-2.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%

Questions About CUE

What is the current price of Cue Biopharma?

Cue Biopharma is trading at $34.20 per share.

What is the 52-week range for Cue Biopharma?

Over the past 52 weeks, Cue Biopharma has traded between $4.97 and $45.50.

How much debt does Cue Biopharma have?

As of the most recent reporting period, Cue Biopharma reported total debt of $3.44M.

How much cash does Cue Biopharma have on hand?

Cue Biopharma reported $16.38M in cash and cash equivalents in its most recent financial results.

What is Cue Biopharma’s dividend yield?

Cue Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services